A Journey Through Time: Trace Pfizer's Evolution From 1849 To 2015
This article was originally published in Scrip
Executive Summary
Pfizer Inc. this week has signed its biggest deal to date, agreeing to pay $160bn for Allergan Inc., to unshackle itself from a US corporate tax regime and create a pharmaceutical business that will dominate the industry.
You may also be interested in...
Six New Molecules By 2030 – J&J’s Neuroscience Strategy
Can neuroscience be precise? Peter Fang, worldwide VP of neuroscience, explains J&J's approach to precision medicine in Alzheimer’s disease, depression and other neurological conditions.
Accessing Venture Debt From The EIB
Tips from Gergely Krajcsi, senior investment officer at the European Investment Bank, on how biotechs can access loans for faster growth.
In Vivo's 2024 Rising Leaders At A Glance
Top 30 leaders: see the list of industry influencers highlighted in the fifth edition of In Vivo's Rising Leaders series.